The present treatise chronicles one decade of experience pertaining to clinical PRRT services in a large-volume tertiary cancer care centre in India delivering over 4,000 therapies, an exemplar of successful PRRT programme employing indigenous 177 Lutetium production and resources. For the purpose of systematic discussion, we have sub-divided the communication into 3 specific parts:(a) Radiopharmaceutical aspects that describes 177 Lutetium production through ‘Direct’Neutron Activation Route and the subsequent radiolabeling procedures,(b) The specific clinical nuances and finer learning points (apart from the routine standard procedure) based upon clinical experience and how it has undergone practice evolution in our setting and (c) Dosimetry results with this indigenous product and radiation safety/health physics aspects involved in PRRT services. Initiated in 2010 at our centre, the PRRT programme is a perfect example of affordable quality health care delivery, with indigenous production of the radionuclide (177 Lu) in the reactor and subsequent radiolabeling of the radiopharmaceutical ([177 Lu] Lu-DOTATATE) at the hospital radiopharmacy unit of the centre, which enabled catering to the needs of a large number of patients of progressive, metastatic and advanced Neuroendocrine Neoplasms (NENs) and related malignancies.